Exon Skipping

DNA Diagnostics and Exon Skipping.-Bioinformatics and Mutations Leading to Exon Skipping.-Minigenes to Confirm Exon Skipping Mutations.-Analysis and Interpretation of RNA Splicing Alterations in Genes Involved in Genetic Disorders.-Exon Skipping Mutations in Neurofibromatosis.-Overview on Applications of Antisense-mediated Exon Skipping.-Overview on DMD Exon Skipping.-Overview on AON Design.-Optimizing RNA/ENA Chimeric Antisense Oligonucleotides Using in vitro Splicing.-Optimizing Antisense Oligonucleotides using Phosphorodiamidate Morpholino Oligomers.-Optimizing Splice Switching Oligomer Sequences using 2’-O-methyl Phosphorothioate Chemistry.-Exon Skipping Quantification by Real Time PCR.-Antisense-mediated Exon Skipping to Shift Alternative Splicing to Treat Cancer.-Antisense-mediated Exon Skipping to Generate Soluble Receptors.-Antisense-mediated Exon Skipping to Reframe Transcripts.-U1 snRNA as an Effective Vector for Stable Expression of Antisense Molecules andfor the Inhibition of the Splicing Reaction.-Engineering U7snRNA Gene to Reframe Transcripts.-Dynamic Fluorescent and Luminescent Reporters for Cell Based Splicing Screens.-Antisense-mediated Exon Skipping to Induce Gene Knockdown.-Antisense-mediated Exon Inclusion.-Antisense Genes to Induce Exon Inclusion.-Using Mini-genes to Identify Factors that Modulate Alternative Splicing.-Overview of Alternative Oligonucleotide Chemistries for Exon Skipping.-Identification of Peptides for Tissue Specific Delivery .-Systemic Delivery of Antisense Oligomer in Animal Models and its Implications for Treating DMD.-Cell-penetrating Peptides Enhance Systemic Delivery of Antisense Morpholino Oligomers.-Optimizing Tissue-specific Antisense Oligonucleotide-peptide Conjugates.